Cargando…

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

Progressive airflow limitation is a hallmark feature of chronic obstructive pulmonary disease (COPD) that ultimately leads to breathlessness, impaired quality of life, and reduced exercise capacity. Pharmacotherapy is used in patients with COPD to prevent and control symptoms, reduce both the freque...

Descripción completa

Detalles Bibliográficos
Autor principal:	D’Urzo, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753168/ https://www.ncbi.nlm.nih.gov/pubmed/23990727 http://dx.doi.org/10.2147/TCRM.S30317

Ejemplares similares

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
por: D'Urzo, Anthony, et al.
Publicado: (2011)

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
por: Beeh, Kai M, et al.
Publicado: (2012)

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
por: Kerwin, Edward, et al.
Publicado: (2012)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials
por: D’Urzo, Anthony, et al.
Publicado: (2018)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
por: Mantero, Marco, et al.
Publicado: (2018)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data
por: D’Urzo, Anthony D, et al.
Publicado: (2015)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
por: Ulrik, Charlotte Suppli
Publicado: (2012)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

A novel model-based approach for dose determination of glycopyrronium bromide in COPD
por: Arievich, Helen, et al.
Publicado: (2012)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review
por: Miravitlles, Marc, et al.
Publicado: (2016)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
por: Brittain, Dominic, et al.
Publicado: (2022)

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective
por: Singh, Dave, et al.
Publicado: (2019)

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
por: Bateman, Eric D., et al.
Publicado: (2015)

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
por: Singh, Dave, et al.
Publicado: (2017)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: D’Urzo, Anthony, et al.
Publicado: (2017)

COPD and glycopyrronium responsiveness assessment: An appraisal
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2023)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease
por: D’Urzo, Anthony, et al.
Publicado: (2015)

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial
por: Frith, Peter A, et al.
Publicado: (2015)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Effectiveness of glycopyrronium bromide in the treatment of small airway dysfunction: A retrospective study
por: Petrone, Albino, et al.
Publicado: (2022)

Is the family physician an accomplice in the development of the ‘primary care gap’? The importance of high quality real-life primary care respiratory research
por: D'Urzo, Anthony
Publicado: (2013)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
por: Dhungana, Santosh, et al.
Publicado: (2017)

The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients
por: Sanguinetti, Claudio M
Publicado: (2014)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
por: Wang, Chen, et al.
Publicado: (2015)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cr9tgarl1k76s1bb23cekpmaaj